Intellia Therapeutics Inc buy Canaccord Genuity Group Inc.
Start price
13.04.23
/
50%
€33.50
Target price
13.04.24
€59.72
Performance (%)
-29.85%
End price
14.04.24
€23.50
Summary
This prediction ended on 14.04.24 with a price of €23.50. The prediction for Intellia Therapeutics Inc disappointed with a performance of -29.85%. Canaccord_Genuity_Gr has a follow-up prediction for Intellia Therapeutics Inc where he still thinks Intellia Therapeutics Inc is a Buy. Canaccord_Genuity_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intellia Therapeutics Inc | 7.009% | 7.009% | 89.410% | -63.930% |
| iShares Core DAX® | 4.244% | 2.864% | 14.030% | 49.549% |
| iShares Nasdaq 100 | 4.890% | 2.814% | 32.707% | 85.974% |
| iShares Nikkei 225® | 9.397% | 7.826% | 48.296% | 63.319% |
| iShares S&P 500 | 3.528% | 1.950% | 25.247% | 62.380% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $66.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten
Current prediction by Canaccord_Genuity_Gr for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€11.99
03.03.26
03.03.26
€41.04
03.03.27
03.03.27
3.46%
21:54
21:54
